RNA dysregulation in diseases of motor neurons

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 323-352

  Ibrahim, Fadia ^a   Nakaya, Tadashi ^a   Mourelatos, Zissimos ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; IGHMBP2; RNP; SMN; Spinal muscular atrophy; TDP 43

Indexed keywords

ANGIOGENIN; COPPER ZINC SUPEROXIDE DISMUTASE; ELONGATOR PROTEIN 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN; RNA; RNA BINDING PROTEIN; SENATAXIN; SMALL NUCLEAR RIBONUCLEOPROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TAR DNA BINDING PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMYOTROPHIC LATERAL SCLEROSIS; AUTOSOMAL RECESSIVE DISORDER; CELL SURVIVAL; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; HIGH THROUGHPUT SEQUENCING; HOUSEKEEPING GENE; HUMAN; IMMUNOPRECIPITATION; LETHAL CONGENITAL CONTRACTURE SYNDROME; LONG TERMINAL REPEAT; LOSS OF FUNCTION MUTATION; MOTOR NEURON DISEASE; NERVE FIBER TRANSPORT; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; RNA BINDING; RNA DEGRADATION; RNA PROCESSING; RNA SEQUENCE; RNA STABILITY; RNA TRANSLATION; SPINAL MUSCULAR ATROPHY; SPINAL MUSCULAR ATROPHY WITH RESPIRATORY DISTRESS TYPE 1;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; MOTOR NEURON DISEASE; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; NERVE DEGENERATION; RNA; RNA-BINDING PROTEINS;

EID: 84856936343     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130307     Document Type: Review

References (206)

1. Dion PA, Daoud H, Rouleau GA. 2009. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat. Rev. Genet. 10:769-82
2. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, et al. 1995. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155-65
3. Lorson CL, Hahnen E, Androphy EJ, Wirth B. 1999. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96:6307-11 (Pubitemid 29256661)
4. Lorson CL, Strasswimmer J, Yao JM, Baleja JD, Hahnen E, et al. 1998. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19:63-66 (Pubitemid 28242025)
5. Cho S, Dreyfuss G. 2010. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. 24:438-42
6. Buhler D, Raker V, Luhrmann R, Fischer U. 1999. Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly: implications for spinal muscular atrophy. Hum. Mol. Genet. 8:2351-57
7. Charroux B, Pellizzoni L, Perkinson RA, Shevchenko A, Mann M, Dreyfuss G. 1999. Gemin3: a novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems. J. Cell Biol. 147:1181-94
8. Pellizzoni L, Charroux B, Dreyfuss G. 1999. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc. Natl. Acad. Sci. USA 96:11167-72 (Pubitemid 29487352)
9. Mourelatos Z, Abel L, Yong J, Kataoka N, Dreyfuss G. 2001. SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J. 20:5443-52 (Pubitemid 32959464)
10. Sun Y, Grimmler M, Schwarzer V, Schoenen F, Fischer U, Wirth B. 2005. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Hum. Mutat. 25:64-71 (Pubitemid 40075915)
11. Otter S, Grimmler M, Neuenkirchen N, Chari A, Sickmann A, Fischer U. 2007. A comprehensive interaction map of the human survival of motor neuron (SMN) complex. J. Biol. Chem. 282:5825-33 (Pubitemid 47093793)
12. Liu Q, Dreyfuss G. 1996. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15:3555-65 (Pubitemid 26239768)
13. Liu Q, Fischer U, Wang F, Dreyfuss G. 1997. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 90:1013-21 (Pubitemid 27408515)
14. Fischer U, Liu Q, Dreyfuss G. 1997. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 90:1023-29 (Pubitemid 27408516)
15. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, et al. 2008. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133:585-600 (Pubitemid 351636302)
16. Yong J, Wan L, Dreyfuss G. 2004. Why do cells need an assembly machine for RNA-protein complexes? Trends Cell Biol. 14:226-32 (Pubitemid 38591326)
17. Yong J, Kasim M, Bachorik JL, Wan L, Dreyfuss G. 2010. Gemin5 delivers snRNA precursors to the SMN complex for snRNP biogenesis. Mol. Cell 38:551-62
18. Pellizzoni L, Yong J, Dreyfuss G. 2002. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298:1775-79 (Pubitemid 35404118)
19. Pellizzoni L. 2007. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep. 8:340-45 (Pubitemid 46511034)
20. Chari A, Golas MM, Klingenhager M, Neuenkirchen N, Sander B, et al. 2008. An assembly chaperone collaborates with the SMN complex to generate spliceosomal snRNPs. Cell 135:497-509
21. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, et al. 2000. Amousemodel for spinal muscular atrophy. Nat. Genet. 24:66-70
22. Chan YB, Miguel-Aliaga I, Franks C, Thomas N, Trulzsch B, et al. 2003. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet. 12:1367-76 (Pubitemid 36758450)
23. Winkler C, Eggert C, Gradl D, Meister G, Giegerich M, et al. 2005. ReducedUsnRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev. 19:2320-30 (Pubitemid 41396909)
24. Boon KL, Xiao S, McWhorterML, Donn T, Wolf-Saxon E, et al. 2009. Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects. Hum. Mol. Genet. 18:3615-25
25. Briese M, Esmaeili B, Fraboulet S, Burt EC, Christodoulou S, et al. 2009. Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinalmuscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum. Mol. Genet. 18:97-104
26. Monani UR. 2005. Spinal muscular atrophy: a deficiency in a ubiquitous protein; amotor neuron-specific disease. Neuron 48:885-96 (Pubitemid 41814694)
27. Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, et al. 2008. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17:2552-69
28. Shpargel KB, Matera AG. 2005. Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins. Proc. Natl. Acad. Sci. USA 102:17372-77 (Pubitemid 41740873)
29. Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, Pellizzoni L. 2007. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE 2:e921
30. Grohmann K, Schuelke M, Diers A, Hoffmann K, Lucke B, et al. 2001. Mutations in the gene encoding immunoglobulin α-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat. Genet. 29:75-77 (Pubitemid 32801813)
31. Molnar GM, Crozat A, Kraeft SK, Dou QP, Chen LB, Pardee AB. 1997. Association of the mammalian helicase MAH with the pre-mRNA splicing complex. Proc. Natl. Acad. Sci. USA 94:7831-36 (Pubitemid 27343734)
32. Guenther UP, Handoko L, Laggerbauer B, Jablonka S, Chari A, et al. 2009. IGHMBP2 is a ribosomeassociated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1). Hum. Mol. Genet. 18:1288-300
33. Kerr D, Khalili K. 1991. A recombinant cDNA derived from human brain encodes a DNA binding protein that stimulates transcription of the human neurotropic virus JCV. J. Biol. Chem. 266:15876-81 (Pubitemid 21907739)
34. Fukita Y, Mizuta TR, Shirozu M, Ozawa K, Shimizu A, Honjo T. 1993. The human Sbp-2, a DNAbinding protein specific to the single-stranded guanine-rich sequence related to the immunoglobulin α chain switch region. J. Biol. Chem. 268:17463-70 (Pubitemid 23236989)
35. Grohmann K, Rossoll W, Kobsar I, Holtmann B, Jablonka S, et al. 2004. Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1). Hum. Mol. Genet. 13:2031-42 (Pubitemid 39377827)
36. de Planell-Saguer M, Schroeder DG, Rodicio MC, Cox GA, Mourelatos Z. 2009. Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. Hum. Mol. Genet. 18:2115-26
37. Hoang T, Peng WT, Vanrobays E, Krogan N, Hiley S, et al. 2005. Esf2p, a U3-associated factor required for small-subunit processome assembly and compaction. Mol. Cell. Biol. 25:5523-34 (Pubitemid 40853587)
38. Cox GA, Mahaffey CL, Frankel WN. 1998. Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele. Neuron 21:1327-37 (Pubitemid 29022535)
39. Maddatu TP, Garvey SM, Schroeder DG, Hampton TG, Cox GA. 2004. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum. Mol. Genet. 13:1105-15 (Pubitemid 38786993)
40. Vuopala K, Herva R. 1994. Lethal congenital contracture syndrome: further delineation and genetic aspects. J. Med. Genet. 31:521-27 (Pubitemid 24226397)
41. Makela-Bengs P, Jarvinen N, Vuopala K, Suomalainen A, Ignatius J, et al. 1998. Assignment of the disease locus for lethal congenital contracture syndrome to a restricted region of chromosome 9q34, by genome scan using five affected individuals. Am. J. Hum. Genet. 63:506-16 (Pubitemid 30418632)
42. Nousiainen HO, Kestila M, Pakkasjarvi N, Honkala H, Kuure S, et al. 2008. Mutations inmRNA export mediator GLE1 result in a fetal motoneuron disease. Nat. Genet. 40:155-57 (Pubitemid 351171396)
43. Narkis G, Ofir R, Manor E, Landau D, Elbedour K, Birk OS. 2007. Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation inERBB3(Her3), a modulator of the phosphatidylinositol- 3-kinase/Akt pathway. Am. J. Hum. Genet. 81:589-95 (Pubitemid 47330217)
44. Narkis G, Ofir R, Landau D, Manor E, Volokita M, et al. 2007. Lethal contractural syndrome type 3 (LCCS3) is caused by a mutation in PIP5K1C, which encodes PIPKI of the phophatidylinsitol pathway. Am. J. Hum. Genet. 81:530-39 (Pubitemid 47330211)
45. Murphy R, Wente SR. 1996. An RNA-export mediator with an essential nuclear export signal. Nature 383:357-60 (Pubitemid 26321769)
46. Watkins JL, Murphy R, Emtage JL, Wente SR. 1998. The human homologue of Saccharomyces cerevisiae Gle1p is required for poly(A)+ RNA export. Proc. Natl. Acad. Sci. USA 95:6779-84 (Pubitemid 28278057)
47. Kendirgi F, Barry DM, Griffis ER, Powers MA, Wente SR. 2003. An essential role for hGle1 nucleocytoplasmic shuttling in mRNA export. J. Cell Biol. 160:1029-40 (Pubitemid 36443872)
48. Alcazar-Roman AR, Tran EJ, Guo S, Wente SR. 2006. Inositol hexakisphosphate and Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export. Nat. Cell Biol. 8:711-16
49. Weirich CS, Erzberger JP, Flick JS, Berger JM, Thorner J, Weis K. 2006. Activation of the DExD/Hbox protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator InsP6 is required for mRNA export. Nat. Cell Biol. 8:668-76
50. Montpetit B, Thomsen ND, Helmke KJ, Seeliger MA, Berger JM, Weis K. 2011.Aconserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export. Nature 472:238-42
51. Pakkasjarvi N, Kerosuo L, Nousiainen H, Gentile M, Saharinen J, et al. 2007. Neural precursor cells from a fatal human motoneuron disease differentiate despite aberrant gene expression. Dev. Neurobiol. 67:270-84
52. Cleveland DW, Rothstein JD. 2001. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2:806-19 (Pubitemid 33674062)
53. Rothstein JD. 2009. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65(Suppl. 1):3-9
54. Geser F, Lee VM, Trojanowski JQ. 2010. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 30:103-12
55. Ilieva H, Polymenidou M, Cleveland DW. 2009. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187:761-72
56. RosenDR. 1993. Mutations inCu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364:362 (Pubitemid 23265284)
57. NeumannM, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130-33 (Pubitemid 44547757)
58. Arai T, Hasegawa M, AkiyamaH, Ikeda K, Nonaka T, et al. 2006. TDP-43 is a component of ubiquitinpositive α-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351:602-11 (Pubitemid 44708852)
59. Buratti E, Baralle FE. 2010. Themultiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 7:420-29
60. Chen-Plotkin AS, Lee VM, Trojanowski JQ. 2010. TARDNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6:211-20
61. Cook SA, Johnson KR, Bronson RT, Davisson MT. 1995. Neuromuscular degeneration (NMD): a mutation on mouse chromosome 19 that causes motor neuron degeneration. Mamm. Genome 6:187-91
62. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. 2005. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 280:37572-84 (Pubitemid 41642366)
63. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, et al. 2008. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 63:535-38 (Pubitemid 351614720)
64. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668-72 (Pubitemid 351432505)
65. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al. 2008. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40:572-74 (Pubitemid 351601218)
66. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, et al. 2008. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 7:409-16
67. Lagier-Tourenne C, Cleveland DW. 2009. Rethinking ALS: the FUS about TDP-43. Cell 136:1001-4
68. Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, et al. 2008. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 121:3778-85
69. Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, et al. 2011. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 30:277-88
70. Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, et al. 2008. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. Neurol. 63:538-42 (Pubitemid 351614721)
71. Tan CF, Eguchi H, Tagawa A, Onodera O, IwasakiT, et al. 2007. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosiswith orwithoutSOD1gene mutation. Acta Neuropathol. 113:535-42 (Pubitemid 46672599)
72. Mori F, Tanji K, Zhang HX, Nishihira Y, Tan CF, et al. 2008. Maturation process of TDP-43- positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 116:193-203
73. Giordana MT, Piccinini M, Grifoni S, De Marco G, Vercellino M, et al. 2010. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 20:351-60
74. Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, et al. 2009. Proteolytic processing of TAR DNA binding protein 43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J. Neurochem. 110:1082-94
75. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, et al. 2009. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA 106:7607-12
76. Pesiridis GS, Tripathy K, Tanik S, Trojanowski JQ, Lee VM. 2011. A "two hit" hypothesis for inclusion formation by carboxy terminal fragments of TDP-43 linked to RNAdepletion and impaired microtubule dependent transport. J. Biol. Chem. 286:18845-55
77. Che MX, Jiang YJ, Xie YY, Jiang LL, Hu HY. 2011. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J. 25:2344-53
78. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. 2010. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30:639-49
79. Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, et al. 2011. Dysregulation of the ALSassociated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Investig. 121:726-38
80. Freibaum BD, Chitta RK, High AA, Taylor JP. 2010. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 9:1104-20
81. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, et al. 2011. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J. Biol. Chem. 286:1204-15
82. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, et al. 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069-75
83. Wang IF, Wu LS, Shen CK. 2008. TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol. Med. 14:479-85
84. Moisse K, Mepham J, Volkening K, Welch I, Hill T, Strong MJ. 2009. Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL-/- mice: support for a role for TDP-43 in the physiological response to neuronal injury. Brain Res. 1296:176-86
85. Sato T, Takeuchi S, Saito A, DingW, Bamba H, et al. 2009. Axonal ligation induces transient redistribution of TDP-43 in brainstem motor neurons. Neuroscience 164:1565-78
86. Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ. 2009. TarDNAbinding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 1305:168-82
87. Strong MJ. 2010. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 288:1-12
88. Ge WW, Volkening K, Leystra-Lantz C, Jaffe H, Strong MJ. 2007. 14-3-3 protein binds to the low molecular weight neurofilament (NFL) mRNA 3′ UTR. Mol. Cell. Neurosci. 34:80-87 (Pubitemid 46026930)
89. Buratti E, Baralle FE. 2008. Multiple roles ofTDP-43 in gene expression, splicing regulation, and human disease. Front. Biosci. 13:867-78 (Pubitemid 351594732)
90. Wang HY, Wang IF, Bose J, Shen CK. 2004. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83:130-39 (Pubitemid 37518267)
91. Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, et al. 2005. Human, Drosophila, and C. elegans TDP-43: nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 348:575-88 (Pubitemid 40515670)
92. Camats M, Guil S, Kokolo M, Bach-Elias M. 2008. P68 RNA helicase (DDX5) alters activity of cis- and trans-acting factors of the alternative splicing of H-Ras. PLoS ONE 3:e2926
93. Buratti E, Baralle FE. 2001. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 276:36337-43
94. Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. 2005. Depletion of TDP43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res. 33:6000-10 (Pubitemid 41742619)
95. Ayala YM, Pagani F, Baralle FE. 2006. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett. 580:1339-44 (Pubitemid 43221997)
96. Bose JK, Wang IF, Hung L, Tarn WY, Shen CK. 2008. TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J. Biol. Chem. 283:28852-59
97. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. 2008. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA 105:6439-44 (Pubitemid 351758364)
98. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. 2009. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284:20329-39
99. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. 2009. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 106:18809-14
100. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, et al. 2010. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 107:3858-63
101. Li Y, Ray P, Rao EJ, Shi C, Guo W, et al. 2010. A Drosophila model for TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA 107:3169-74
102. Voigt A, Herholz D, Fiesel FC, Kaur K, Muller D, et al. 2010. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE 5:e12247
103. Zhou H, Huang C, Chen H, Wang D, Landel CP, et al. 2010. Transgenic ratmodel of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 6:e1000887
104. Shan X, Chiang PM, Price DL, Wong PC. 2010. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. USA 107:16325-30
105. Swarup V, Julien JP. 2011. ALS pathogenesis: recent insights from genetics and mouse models. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:363-69
106. Licatalosi DD, Mele A, Fak JJ, Ule J, Kayikci M, et al. 2008. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 456:464-69 (Pubitemid 352759008)
107. Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460:479-86
108. Dreyfuss G, Choi YD, Adam SA. 1984. Characterization of heterogeneous nuclear RNA-protein complexes in vivo with monoclonal antibodies. Mol. Cell. Biol. 4:1104-14 (Pubitemid 14050727)
109. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. 2003. CLIP identifies Nova-regulated RNA networks in the brain. Science 302:1212-15 (Pubitemid 37421026)
110. Wang Z, Gerstein M, Snyder M. 2009. RNA-seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10:57-63
111. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, et al. 2011. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14:459-68
112. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, et al. 2011. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14:452-58
113. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. 2003. The deacetylaseHDAC6regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-38 (Pubitemid 38030301)
114. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. 2010. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J. Cell Biol. 189:671-79
115. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205-8
116. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, et al. 2009. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208-11
117. Suzuki N, Aoki M, Warita H, Kato M, Mizuno H, et al. 2010. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. J. Hum. Genet. 55:252-54
118. Tateishi T, Hokonohara T, Yamasaki R, Miura S, Kikuchi H, et al. 2010. Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol. 119:355-64
119. Deng HX, ZhaiH, Bigio EH, Yan J, Fecto F, et al. 2010. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 67:739-48
120. Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, et al. 2010. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA 107:13318-23
121. Belzil VV, Daoud H, Dion PA, Rouleau GA. 2011. No effect on SOD1 splicing by TARDP or FUS mutations. Arch. Neurol. 68:395-96
122. Lagier-Tourenne C, Polymenidou M, Cleveland DW. 2010. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 19:46-64R
123. Corrado L, Del Bo R, Castellotti B, Ratti A, Cereda C, et al. 2010. Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J. Med. Genet. 47:190-94
124. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, et al. 2009. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117:137-49
125. Li Q, Lee JA, Black DL. 2007. Neuronal regulation of alternative pre-mRNA splicing. Nat. Rev. Neurosci. 8:819-31 (Pubitemid 350006218)
126. Rapp TB, Yang L, Conrad EU 3rd, Mandahl N, Chansky HA. 2002. RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. J. Orthop. Res. 20:723-29 (Pubitemid 34822991)
127. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F. 1998. The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS. J. Biol. Chem. 273:4838-42 (Pubitemid 28108632)
128. Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A. 2003. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins. Exp. Cell Res. 283:184-95 (Pubitemid 36269024)
129. Zinszner H, Albalat R, Ron D. 1994. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 8:2513-26 (Pubitemid 24347243)
130. Rappsilber J, RyderU, Lamond AI, Mann M. 2002. Large-scale proteomic analysis of the human spliceosome. Genome Res. 12:1231-45 (Pubitemid 41264425)
131. Kameoka S, Duque P, Konarska MM. 2004. p54nrb associates with the 5′ splice site within large transcription/ splicing complexes. EMBO J. 23:1782-91 (Pubitemid 38649641)
132. Wu S, Green MR. 1997. Identification of a human protein that recognizes the 3′ splice site during the second step of pre-mRNA splicing. EMBO J. 16:4421-32 (Pubitemid 27298195)
133. Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F. 2010. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 277:2268-81
134. Belly A, Moreau-Gachelin F, Sadoul R, Goldberg Y. 2005. Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: exclusion from the nucleus and accumulation in dendritic granules and spine heads. Neurosci. Lett. 379:152-57 (Pubitemid 40544525)
135. Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, et al. 2005. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr. Biol. 15:587-93 (Pubitemid 40413401)
136. Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, et al. 2000. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat. Genet. 24:175-79 (Pubitemid 30094720)
137. Selamat W, Jamari I, Wang Y, Takumi T, Wong F, Fujii R. 2009. TLS interaction with NMDA R1 splice variant in retinal ganglion cell line RGC-5. Neurosci. Lett. 450:163-66
138. Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, et al. 2010. MutantFUSproteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 19:4160-75
139. Gal J, Zhang J, Kwinter DM, Zhai J, Jia H, et al. 2011. Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol. Aging 32:2323.e27-40
140. KovarH. 2011. Dr. Jekyll and Mr.Hyde: the two faces of the FUS/EWS/TAF15 protein family. Sarcoma 2011:837474
141. Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, et al. 2008. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 9:37
142. Spitzer JI, Ugras S, Runge S, Decarolis P, Antonescu C, et al. 2011. mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes Cancer 50:338-47
143. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. 1996. hTAFII68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15:5022-31 (Pubitemid 26315812)
144. Thomas MC, Chiang CM. 2006. The general transcription machinery and general cofactors. Crit. Rev. Biochem. Mol. Biol. 41:105-78
145. Jobert L, Argentini M, Tora L. 2009. PRMT1mediated methylation ofTAF15 is required for its positive gene regulatory function. Exp. Cell Res. 315:1273-86
146. Jobert L, Pinzon N, Van Herreweghe E, Jady BE, Guialis A, et al. 2009. Human U1 snRNA forms a new chromatin-associated snRNP with TAF15. EMBO Rep. 10:494-500
147. Law WJ, Cann KL, Hicks GG. 2006. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief. Funct. Genomics 5:8-14 (Pubitemid 46402988)
148. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, et al. 2004. Themicroprocessor complex mediates the genesis of microRNAs. Nature 432:235-40 (Pubitemid 39545855)
149. Wu D, Yu W, Kishikawa H, Folkerth RD, Iafrate AJ, et al. 2007. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62:609-17
150. Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, et al. 2008. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics 9:33-40
151. Paubel A, Violette J, Amy M, Praline J, Meininger V, et al. 2008. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol. 65:1333-36
152. Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, et al. 2010. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 47:554-60
153. Moroianu J, Riordan JF. 1994. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA 91:1677-81 (Pubitemid 24080268)
154. Lee S, Wu Z, Sandberg K, Yoo SE, Maric C. 2006. Posttranscriptionalmechanisms contribute to osmotic regulation of ANG type 1 receptors in cultured rat renomedullary interstitial cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:44-49
155. Li S, Hu GF. 2010. Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int. J. Biochem. Mol. Biol. 1:26-35
156. Subramanian V, Feng Y. 2007. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 16:1445-53 (Pubitemid 47055116)
157. Sebastia J, Kieran D, Breen B, King MA, Netteland DF, et al. 2009. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 16:1238-47
158. Yamasaki S, Ivanov P, Hu GF, Anderson P. 2009. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 185:35-42
159. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, et al. 2004. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74:1128-35 (Pubitemid 38669312)
160. Suraweera A, Becherel OJ, Chen P, Rundle N, Woods R, et al. 2007. Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidativeDNAdamage. J. Cell Biol. 177:969-79 (Pubitemid 46955702)
161. Mendell JT, ap Rhys CMJ, Dietz HC. 2002. Separable roles for rent1/hUpf1 in altered splicing and decay of nonsense transcripts. Science 298:419-22 (Pubitemid 35176351)
162. MoreiraMC, Klur S, Watanabe M, Nemeth AH, Le Ber I, et al. 2004. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat. Genet. 36:225-27 (Pubitemid 38282744)
163. Suraweera A, Lim Y, Woods R, Birrell GW, Nasim T, et al. 2009. Functional role for senataxin, defective in ataxia oculomotor apraxia type 2, in transcriptional regulation. Hum. Mol. Genet. 18:3384-96
164. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao GX, et al. 2009. A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10:118-22
165. Hirano M, Quinzii CM, Mitsumoto H, Hays AP, Roberts JK, et al. 2010. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 12:223-27
166. Chen YZ, Hashemi SH, Anderson SK, Huang Y, Moreira MC, et al. 2006. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol. Dis. 23:97-108 (Pubitemid 43903634)
167. Simpson CL, Lemmens R, Miskiewicz K, Broom WJ, Hansen VK, et al. 2009. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum. Mol. Genet. 18:472-81
168. Winkler GS, Kristjuhan A, Erdjument-Bromage H, Tempst P, Svejstrup JQ. 2002. Elongator is a histone H3 and H4 acetyltransferase important for normal histone acetylation levels in vivo. Proc. Natl. Acad. Sci. USA 99:3517-22 (Pubitemid 34252140)
169. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, et al. 2001. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet. 68:598-605 (Pubitemid 32202755)
170. Huang B, JohanssonMJ, Bystrom AS. 2005. An early step in wobble uridine tRNA modification requires the Elongator complex. RNA 11:424-36 (Pubitemid 40397176)
171. Otero G, Fellows J, Li Y, de Bizemont T, Dirac AM, et al. 1999. Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol. Cell 3:109-18 (Pubitemid 29292482)
172. Han Q, Lu J, Duan J, Su D, Hou X, et al. 2008. Gcn5- and Elp3-induced histoneH3 acetylation regulates hsp70 gene transcription in yeast. Biochem. J. 409:779-88 (Pubitemid 351214204)
173. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, et al. 2008. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321:1218-21
174. Shatkin AJ, Manley JL. 2000. The ends of the affair: capping and polyadenylation. Nat. Struct. Biol. 7:838-42
175. Gebauer F, Hentze MW. 2004. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 5:827-35 (Pubitemid 39336276)
176. Wang Z, Burge CB. 2008. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 14:802-13 (Pubitemid 351574901)
177. Moore MJ, Proudfoot NJ. 2009. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136:688-700
178. Martin KC, Ephrussi A. 2009.mRNAlocalization: gene expression in the spatial dimension. Cell 136:719-30
179. Stewart M. 2010. Nuclear export of mRNA. Trends Biochem. Sci. 35:609-17
180. Houseley J, Tollervey D. 2009. The many pathways of RNA degradation. Cell 136:763-76
181. Isken O, Maquat LE. 2008. The multiple lives of NMD factors: balancing roles in gene and genome regulation. Nat. Rev. Genet. 9:699-712
182. Le Hir H, Gatfield D, Izaurralde E, Moore MJ. 2001. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J. 20:4987-97 (Pubitemid 32848650)
183. Dostie J, Dreyfuss G. 2002. Translation is required to remove Y14 from mRNAs in the cytoplasm. Curr. Biol. 12:1060-67 (Pubitemid 34766927)
184. Sanford JR, Ellis J, Caceres JF. 2005. Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem. Soc. Trans. 33:443-46 (Pubitemid 40873861)
185. Kolb SJ, Battle DJ, Dreyfuss G. 2007. Molecular functions of theSMNcomplex. J. Child Neurol. 22:990-94
186. Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamicRNPmachine. Cell 136:701-18
187. Chari A, Paknia E, Fischer U. 2009. The role of RNP biogenesis in spinal muscular atrophy. Curr. Opin. Cell Biol. 21:387-93
188. Kass S, Tyc K, Steitz JA, Sollner-Webb B. 1990. The U3 small nucleolar ribonucleoprotein functions in the first step of preribosomal RNA processing. Cell 60:897-908
189. Kiss T. 2002. Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 109:145-48 (Pubitemid 34518252)
190. Johnson AW, Lund E, Dahlberg J. 2002. Nuclear export of ribosomal subunits. Trends Biochem. Sci. 27:580-85 (Pubitemid 35335407)
191. Watkins NJ, Lemm I, Ingelfinger D, Schneider C, Hossbach M, et al. 2004. Assembly and maturation of the U3 snoRNP in the nucleoplasm in a large dynamic multiprotein complex. Mol. Cell 16:789-98 (Pubitemid 39586536)
192. Cisterna B, Biggiogera M. 2010. Ribosome biogenesis: from structure to dynamics. Int. Rev. Cell Mol. Biol. 284:67-111
193. Wolin SL, Matera AG. 1999. The trials and travels of tRNA. Genes Dev. 13:1-10 (Pubitemid 29045110)
194. Ibba M, Soll D. 2000. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 69:617-50
195. Schattner P, Brooks AN, Lowe TM. 2005. The tRNAscan-SE, snoscan and snoGPS Web servers for the detection of tRNAs and snoRNAs. Nucleic Acids Res. 33:686-89
196. Hopper AK, Phizicky EM. 2003. tRNA transfers to the limelight. Genes Dev. 17:162-80 (Pubitemid 36105890)
197. Schramm L, Hernandez N. 2002. Recruitment of RNA polymerase III to its target promoters. Genes Dev. 16:2593-620
198. Paushkin SV, Patel M, Furia BS, Peltz SW, Trotta CR. 2004. Identification of a human endonuclease complex reveals a link between tRNA splicing and pre-mRNA 3′ end formation. Cell 117:311-21 (Pubitemid 38534538)
199. Nakanishi K, Nureki O. 2005. Recent progress of structural biology of tRNA processing and modification. Mol. Cells 19:157-66
200. Giege R. 2008. Toward a more complete view of tRNA biology. Nat. Struct. Mol. Biol. 15:1007-14
201. Popow J, Englert M, Weitzer S, Schleiffer A, Mierzwa B, et al. 2011. HSPC117 is the essential subunit of a human tRNA splicing ligase complex. Science 331:760-64
202. Liu X, Fortin K, Mourelatos Z. 2008. MicroRNAs: biogenesis and molecular functions. Brain Pathol. 18:113-21
203. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-33
204. Djuranovic S, Nahvi A, Green R. 2011. A parsimonious model for gene regulation by miRNAs. Science 331:550-53
205. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245-56
206. Renton AE, Majounie E, Waite A, Siḿon-Śanchez J, Rollinson S, et al. 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257-68